Polpharma Biologics – The Polish biosimilar powerhouse

Opublikowany: 17.08.2020

“Other companies come to us and want CDMO work in the biosimilar space because we know what we’re doing, but our goal is not to become 100% biosimilars. Our goal is to become a leading biologics manufacturer and biosimilars are a part of what we do,” said our Vice President of Strategy, Programs and Portfolio – Alexandra Moulson in an interview with The Center for Biosimilars®.

Read the full interview and find out more about Polpharma Biologics CDMO services, forward expansion and whether COVID-19 had an impact on the company in recent months.

Alexandra Moulson
Vice President of Strategy, Programs and Portfolio at Polpharma Biologics

Alexandra Moulson

written by: Polpharma Biologics

Współpracujmy, aby dostarczać wysokiej jakości leki biopodobne.

Skontaktuj się, aby uzyskać więcej informacji.